Jason Westin, Lead of the Lymphoma and Myeloma Service Line at MD Anderson Cancer Center, shared a post on LinkedIn:
“I’m thrilled to share that the SUNMO trial, which I had the privilege of presenting at the Japanese Society of Medical Oncology 2026 Meeting, has led to the official approval of a new treatment for DLBCL by the Japanese Ministry of Health, Labour and Welfare.
Representing our global team of investigators in Japan was an honor, but seeing this work translate into a new standard of care for patients is the ultimate reward.
Congratulations to everyone involved in this milestone!”
Other articles featuring Jason Westin on OncoDaily.